Latest News
All Times Eastern
- ‘It’s caused a lot of tension in our marriage’: My wife’s family comes visit, hides food and never cleans up. How do we get rid of them?
- Barron's China’s AI Clout Might Be Overstated. What to Know.
- Barron's This Company Makes Costco and Amazon’s Store Brands. Its Stock Is a Buy.
- Barron's This Carbon-Capture Stock Has Big Plans. Why It’s a Buy.
- Barron's Forget Apple and Nvidia. Why June Belongs to Small-Caps.
- Barron's Market Gains as Wall of Worry Crumbles. What Happens Next.
- Judge in FTX bankruptcy rejects media challenge, says customer names can remain secret
- Barron's Commercial Traders Are Net Long Copper. That’s a Good Sign for the Red Metal.
- Mark Zuckerberg says Meta may be ‘primary beneficiary’ of Apple Vision Pro headset
- Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
to be replaced
CSL Ltd.
CSLAU
-0.45
-0.15%
Closed
$ 305.30
| Previous Close |
|---|
| $305.75 |
Volume: 515.32K
65 Day Avg: 669.09K
305.07
Day Range
308.77
254.30
52 Week Range
314.28
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
CSL Overview
Key Data
- Open $305.50
- Day Range 305.07 - 308.77
- 52 Week Range 254.30 - 314.28
- Market Cap $147.48B
- Shares Outstanding 482.22M
- Public Float 480.65M
- Beta 0.90
- Rev. per Employee $563.80K
- P/E Ratio 47.78
- EPS $6.39
- Yield 1.09%
- Dividend $1.62
- Ex-Dividend Date Mar 9, 2023
- Short Interest N/A
- % of Float Shorted N/A
- Average Volume 669.09K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 10
Full Ratings
Recent News
UniQure's shares fall on licensing deal for gene therapy
Shares of UniQure tumbled 17% in premarket trading on Thursday, the day after it announced that CSL Behring would acquire exclusive commercialization rights to its gene-therapy program. UniQure will receive a $450 millio...
Australia's CSL cuts outlook on tough competition
SYDNEY--CSL Ltd. (CSL.AU), Australia's largest pharmaceutical company, warned rising competition in the blood-plasma-therapies market will crimp its full-year earnings growth, after posting a small interim profit rise.
Australia's CSL considers bigger stock buyback
SYDNEY-- CSL Ltd., the world's second-biggest blood-products maker, said it would will consider another 950 million Australian dollar (US$880 million) buyback of its own shares after reporting a small rise in annual net pr...
UBS Keeps Their Buy Rating on CSL (CMXHF)
on TipRanks.com
CSL (CMXHF) Gets a Buy from UBS
on TipRanks.com
3 ASX ETFs to Follow
on TipRanks.com
CSL (CMXHF) Receives a Buy from J.P. Morgan
on TipRanks.com
CSL (CMXHF) Receives a Buy from RBC Capital
on TipRanks.com
Two ASX Shares Backed by Analysts
on TipRanks.com
Carlisle Has Solid Growth and Profitability
Carlisle Has Solid Growth and Profitability
on GuruFocus.com
Lodge Hill Capital, LLC Buys 2, Sells 3 in 4th Quarter
Lodge Hill Capital, LLC Buys 2, Sells 3 in 4th Quarter
on GuruFocus.com
Citigroup Sticks to Its Buy Rating for CSL (CMXHF)
on TipRanks.com
ABN Amro Sticks to Its Buy Rating for CSL (CMXHF)
on TipRanks.com
Morgan Stanley Reaffirms Their Buy Rating on CSL (CMXHF)
on TipRanks.com
Should Investors Worry About Carlisle Companies Inc's Insider Sells?
Should Investors Worry About Carlisle Companies Inc's Insider Sells?
on GuruFocus.com
CSL and CPU: ASX Stock Earnings in this Week
on TipRanks.com
Wilsons Sticks to Its Buy Rating for CSL (CMXHF)
on TipRanks.com
Top 5 4th Quarter Trades of Spire Wealth Management
Top 5 4th Quarter Trades of Spire Wealth Management
on GuruFocus.com
These two ASX Stocks are off to a Good Start in 2023
on TipRanks.com
DEROY & DEVEREAUX PRIVATE INVESTMENT COUNSEL INC Buys 2, Sells 3 in 4th Quarter
DEROY & DEVEREAUX PRIVATE INVESTMENT COUNSEL INC Buys 2, Sells 3 in 4th Quarter
on GuruFocus.com
Top 5 4th Quarter Trades of Leith Wheeler Investment Counsel Ltd.
Top 5 4th Quarter Trades of Leith Wheeler Investment Counsel Ltd.
on GuruFocus.com
Here's Why Hold Strategy is Beneficial for Carlisle (CSL)
Carlisle's (CSL) CCM segment stands to benefit from solid momentum in the U.S. reroofing end-market and new construction activity. Its efforts to reward shareholders with dividends augur well.
on Zacks.com
CSL Ltd.
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring and CSL Seqirus. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The CSL Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Starpharma Holdings Ltd. | $151.88M | |
| Bionomics Ltd. | $27.91M | |
| Living Cell Technologies Ltd. | $17.16M |